Common side effects of GLP-1 receptor agonists are nausea, diarrhea, vomiting, and decreased appetite
Yet while reducing cardiovascular disease by treating high cholesterol, high blood pressure, and diabetes is standard practice, the concept of treating obesity to reduce cardiovascular complications has been hampered by the lack of evidence that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes, said Michael Lincoff, M.D., SELECTs lead author and vice chair for research in Cleveland Clinics Department of Cardiovascular Medicine
If one medication is not producing adequate results, switching to another is preferable to stacking them
As little as 3 percent weight loss can have a meaningful benefit for diabetes, hyperglycemia and dyslipidemia (abnormal lipid levels in the bloodstream, which poses a higher risk for cardiovascular disease)but these conditions, along with many others, often require a greater amount of weight loss to lead to health improvements
When semaglutide degrades through deamidation, hydrolysis, or oxidation, the resulting degradation products typically lack the biological activity of the intact molecule
